
Overview
Dr. Badros has extensive clinical experience in Bone Marrow Transplantation with special interest in multiple myeloma. He was involved in the initial trails of thalidomide and has conducted many clinical trials for treatment of relapsed and refractory multiple myeloma. Dr. Badros research has focused on evaluation of immunological approaches to eradicate residual myeloma cells in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells and non-myeloablative allogeneic donor grafts.</p> Dr. Badros is involved in the development of targeted novel therapeutics. He has completed a gene therapy trial using G-3039 ""Bcl-antisense."" He evaluated the use of the proteosome inhibitor ""bortezomib"" in the newly diagnosed myeloma patients and evaluated the effects of bortezomib on stem cell. Currently, Dr. Badros is evaluating various combinations of novel therapies in multiple myeloma such as Lenalidomide and histone deacetylase inhibitors (SAHA) in relapsed myeloma patients alone and in combinations with dexamethasone and/or bortezomib.</p>.
Dr. Badros is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Transplant.
Dr. Badros is board certified in American Board Of Internal Medicine - Medical Oncology, 1995. He is actively involved in clinical research, co-authoring 96 peer reviewed articles and participating in 4 clinical trials. Dr. Badros is currently accepting new patients.
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
22 South Greene Street, Floor 1, Baltimore, MD 21201
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
4 Clinical Trials
Sidney Kimmel Comprehensive Cancer Center
Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine. Dr. Brodsky is currently accepting new patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner-Johnston is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wagner-Johnston is currently accepting new patients.
Stoler Outpatient Cancer Clinic
Taofeek Owonikoko is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Holdhoff is board certified in American Board Of Internal Medicine. Dr. Holdhoff is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Osteosarcoma, and Salpingo-Oophorectomy. Dr. Meyer is board certified in American Board Of Internal Medicine. Dr. Meyer is currently accepting new patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dezern is board certified in American Board Of Internal Medicine. Dr. Dezern is currently accepting new patients.
Frequently Asked Questions about Dr. Ashraf Z. Badros
How do I make an appointment with Dr. Ashraf Z. Badros?
You can book an appointment with Dr. Ashraf Z. Badros by calling their office at 410-328-7609. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Ashraf Z. Badros a top-rated expert for Multiple Myeloma?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ashraf Z. Badros is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Ashraf Z. Badros specialize in?
While Dr. Ashraf Z. Badros is a Oncology, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Relapsed Refractory Multiple Myeloma (RRMM). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. Ashraf Z. Badros participate in research or clinical trials?
Yes. Dr. Ashraf Z. Badros has published 96 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Ashraf Z. Badros's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Ashraf Z. Badros accept my insurance?
Dr. Ashraf Z. Badros accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 410-328-7609 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Multiple MyelomaDr. Badros isElite. Learn about Multiple Myeloma.
- Smoldering Multiple MyelomaDr. Badros isElite. Learn about Smoldering Multiple Myeloma.
- Distinguished
- Bone Marrow TransplantDr. Badros isDistinguished. Learn about Bone Marrow Transplant.
- Relapsed Refractory Multiple Myeloma (RRMM)Dr. Badros isDistinguished. Learn about Relapsed Refractory Multiple Myeloma (RRMM).
- Waldenstrom MacroglobulinemiaDr. Badros isDistinguished. Learn about Waldenstrom Macroglobulinemia.
- Advanced
- Cyclic NeutropeniaDr. Badros isAdvanced. Learn about Cyclic Neutropenia.
- Dyserythropoietic Anemia and Thrombocytopenia
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- PlasmacytomaDr. Badros isAdvanced. Learn about Plasmacytoma.
- Primary AmyloidosisDr. Badros isAdvanced. Learn about Primary Amyloidosis.
- Schnitzler SyndromeDr. Badros isAdvanced. Learn about Schnitzler Syndrome.
- Experienced
- Acute Lymphoblastic Leukemia (ALL)Dr. Badros isExperienced. Learn about Acute Lymphoblastic Leukemia (ALL).
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Badros isExperienced. Learn about Acute Myeloid Leukemia (AML).
- AgranulocytosisDr. Badros isExperienced. Learn about Agranulocytosis.
- AnemiaDr. Badros isExperienced. Learn about Anemia.
- B-Cell LymphomaDr. Badros isExperienced. Learn about B-Cell Lymphoma.
- Cardiac AmyloidosisDr. Badros isExperienced. Learn about Cardiac Amyloidosis.
- Cerebral Amyloid AngiopathyDr. Badros isExperienced. Learn about Cerebral Amyloid Angiopathy.
- Childhood Acute Myeloid LeukemiaDr. Badros isExperienced. Learn about Childhood Acute Myeloid Leukemia.
- Chronic Familial NeutropeniaDr. Badros isExperienced. Learn about Chronic Familial Neutropenia.
- Classical Hodgkin LymphomaDr. Badros isExperienced. Learn about Classical Hodgkin Lymphoma.
- Diffuse Large B-Cell Lymphoma (DLBCL)Dr. Badros isExperienced. Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
- Febrile NeutropeniaDr. Badros isExperienced. Learn about Febrile Neutropenia.
- Follicular LymphomaDr. Badros isExperienced. Learn about Follicular Lymphoma.
- Gorham's DiseaseDr. Badros isExperienced. Learn about Gorham's Disease.
- Graft Versus Host Disease (GvHD)Dr. Badros isExperienced. Learn about Graft Versus Host Disease (GvHD).
- Hajdu-Cheney SyndromeDr. Badros isExperienced. Learn about Hajdu-Cheney Syndrome.
- Hereditary Cerebral Amyloid AngiopathyDr. Badros isExperienced. Learn about Hereditary Cerebral Amyloid Angiopathy.
- Hodgkin LymphomaDr. Badros isExperienced. Learn about Hodgkin Lymphoma.
- Large-Cell Immunoblastic LymphomaDr. Badros isExperienced. Learn about Large-Cell Immunoblastic Lymphoma.
- LeukemiaDr. Badros isExperienced. Learn about Leukemia.
- Mantle Cell Lymphoma (MCL)Dr. Badros isExperienced. Learn about Mantle Cell Lymphoma (MCL).
- Myelodysplastic Syndrome (MDS)Dr. Badros isExperienced. Learn about Myelodysplastic Syndrome (MDS).
- Non-Hodgkin LymphomaDr. Badros isExperienced. Learn about Non-Hodgkin Lymphoma.
- Osteolysis Syndrome RecessiveDr. Badros isExperienced. Learn about Osteolysis Syndrome Recessive.
- Primary Localized Cutaneous AmyloidosisDr. Badros isExperienced. Learn about Primary Localized Cutaneous Amyloidosis.
- Pure Red Cell AplasiaDr. Badros isExperienced. Learn about Pure Red Cell Aplasia.
- Severe Congenital NeutropeniaDr. Badros isExperienced. Learn about Severe Congenital Neutropenia.
- Skeletal-Extraskeletal AngiomatosisDr. Badros isExperienced. Learn about Skeletal-Extraskeletal Angiomatosis.
- Testicular CancerDr. Badros isExperienced. Learn about Testicular Cancer.
- ThrombocytopeniaDr. Badros isExperienced. Learn about Thrombocytopenia.




